30.98
-0.74%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shenzhen Salubris Pharmaceuticals Co
Its shares trade on Shenzhen under the ticker 002294.SZ. It has been listed since 10 September 2009. In the fiscal year to 31 December 2024, it reported revenue of CN¥4.01bn and net income of CN¥601.6m. At that date it held total assets of CN¥10.47bn and shareholders' equity of CN¥8.71bn.
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2009-09-10. The firm provides two categories of products: pharmaceutical preparation and bulk drugs. The firm is also engaged in the research and development, production and sales of cardiovascular medical devices. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Sept 2009
- Employees
- 3,454
- Website
- salubris.cn ↗
Leadership
Pay as last reported
- Mr. Kevin Sing YeChairman of the Board, since 2007CN¥1.6m
- Mr. Chenghai YeLife Honorary Chairman of the Board, since 2007CN¥186,700
- Ms. Yun KongFinance DirectorCN¥1.3m
- Mr. Jie YanGeneral Manager, Director, since 2013CN¥1.7m
- Mr. Ping ChenDeputy General ManagerCN¥963,700
- Ms. Songping ZhaoDeputy General ManagerCN¥1.1m
- Mr. Jianfeng YangSecretary of the Board, Director, since 2007CN¥936,700
- Ms. Qianyu ChenDirectorCN¥480,800
- Mr. Qing ShenDirector
- Mr. Laiping LiuIndependent DirectorCN¥120,000
- Mr. Xuegong WangIndependent DirectorCN¥120,000
- Mr. Houjia ZhuIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 25
- Social
- 26
- Governance
- 55
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shenzhen Salubris Pharmaceuticals employs 3,454 full-time employees in Health Care sector.
- The company produces pharmaceutical preparations and bulk drugs for domestic and overseas markets.
- Shenzhen Salubris focuses on cardiovascular medical devices research and development.
Weaknesses
- Shenzhen Salubris has no international headquarters outside Shenzhen, China.
- The company's products are limited to pharmaceutical preparations and bulk drugs only.
- Shenzhen Salubris does not have a presence in the Financials or Real Estate sectors.
Opportunities
- Shenzhen Salubris can expand into the Information Technology sector for medical device innovation.
- The company can leverage its domestic market presence to enter new overseas markets.
- Shenzhen Salubris may grow by developing new cardiovascular medical devices.
Threats
- Shenzhen Salubris faces competition from other Health Care companies in China.
- The company's reliance on domestic market sales poses a risk for overseas expansion.
- Shenzhen Salubris must navigate regulatory challenges in the Pharmaceuticals industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.